Cargando…

Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer

PURPOSE: Clinical practice guidelines recommend the use of all approved granulocyte colony-stimulating factors (G-CSFs), including filgrastim and pegfilgrastim, as primary febrile neutropenia (FN) prophylaxis in patients receiving high- or intermediate-risk regimens (in those with additional patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aapro, Matti S., Chaplin, Stephen, Cornes, Paul, Howe, Sebastian, Link, Hartmut, Koptelova, Natalia, Mehl, Andrea, Di Palma, Mario, Schroader, Bridgette Kanz, Terkola, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511548/ https://www.ncbi.nlm.nih.gov/pubmed/37728795 http://dx.doi.org/10.1007/s00520-023-08043-4

Ejemplares similares

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
por: Aapro, Matti, et al.
Publicado: (2010)

The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
por: Li, Edward, et al.
Publicado: (2021)

Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors
por: Kelly, S, et al.
Publicado: (2009)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
por: Wojtukiewicz, Marek, et al.
Publicado: (2014)

Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia
por: Cornes, Paul, et al.
Publicado: (2018)

Correction to: Systematic Review and Meta-analysis of Short-versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia
por: Cornes, Paul, et al.
Publicado: (2018)

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
por: Boccia, Ralph, et al.
Publicado: (2022)

Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study
por: Rapoport, Bernardo Leon, et al.
Publicado: (2018)

Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region
por: Trotta, Francesco, et al.
Publicado: (2017)

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
por: Cooper, Katy L, et al.
Publicado: (2011)

Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level
por: Baig, Hassam, et al.
Publicado: (2018)

Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor
por: Alshari, Osama, et al.
Publicado: (2021)

Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors—A Breakthrough in the Treatment of Cancer Patients with Febrile Neutropenia
por: Căinap, Călin, et al.
Publicado: (2021)

Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors
por: Hapakova, Nikola, et al.
Publicado: (2022)

Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor
por: Dale, David C., et al.
Publicado: (2022)

Dose-Dependent Effect of Granulocyte Transfusions in Hematological Patients with Febrile Neutropenia
por: Teofili, Luciana, et al.
Publicado: (2016)

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
por: Aapro, Matti, et al.
Publicado: (2017)

Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis
por: Aslam, Saad, et al.
Publicado: (2023)

A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
por: Leon Rapoport, Bernardo, et al.
Publicado: (2023)

Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
por: Averin, Ahuva, et al.
Publicado: (2020)

A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia
por: Clemons, Mark, et al.
Publicado: (2021)

Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement
por: Adamo, Vincenzo, et al.
Publicado: (2022)

The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy
por: Halalsheh, Omar M., et al.
Publicado: (2022)

Preventing healthcare-acquired infections in cancer patients with febrile neutropenia in intensive care units: The role of granulocyte-colony stimulating factor prophylaxis
por: Blot, Stijn, et al.
Publicado: (2023)

Preventing healthcare-acquired infections in cancer patients with febrile neutropenia in intensive care units: The role of granulocyte-colony stimulating factor prophylaxis
por: Chou, Hui-Chen, et al.
Publicado: (2023)

The reliability of FEbrile Neutropenia after ChEmotherapy (FENCE) scores in predicting granulocyte colony-stimulating factor breakthrough febrile neutropenia among patients with lymphoma undergoing first-cycle chemotherapy: A prospective observational study
por: Thungthong, Pravinwan, et al.
Publicado: (2023)

Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)
por: Link, Hartmut
Publicado: (2022)

Genomic analysis of the prognostic value of colony-stimulating factors (CSFs) and colony-stimulating factor receptors (CSFRs) across 24 solid cancer types
por: Huang, Xinyi, et al.
Publicado: (2020)

Emerging cancer therapies and granulocyte-colony stimulating factor in febrile neutropenia patients presenting to the emergency department during the COVID-19 pandemic era
por: Lai, Wei-Jen, et al.
Publicado: (2023)

Macrophage Colony‐stimulating Factor Prevents Febrile Neutropenia Induced by Chemotherapy
por: Hidaka, Takao, et al.
Publicado: (2001)

The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials
por: Wang, Li, et al.
Publicado: (2015)

Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework
por: Wang, Weijia, et al.
Publicado: (2021)

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
por: Dotsu, Yosuke, et al.
Publicado: (2021)

Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study
por: Ishikawa, Takashi, et al.
Publicado: (2021)

Granulocyte Colony-stimulating Factor for Preterms with Sepsis and Neutropenia: A Randomized Controlled Trial
por: Chaudhuri, Jasodhara, et al.
Publicado: (2012)

The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study
por: Li, Lei, et al.
Publicado: (2019)

Antineoplastics/granulocyte colony-stimulating factors: Febrile neutropenia, COVID-19, and aggravation of COVID-19 pneumonia and post-COVID-19 organising pneumonia: case report
Publicado: (2022)

Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines
por: Naeem, Doaa, et al.
Publicado: (2018)

Granulocyte-colony-stimulating Factor-resistant Neutropenia and Polyneuropathy Presenting as Severe Complications of Sjögren's Syndrome
por: Tomita, Katsuyuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_euade80i18rn5vmgs1i0osr9lg